We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Wants Another Trial for InterMune’s Esbriet NDA
FDA Wants Another Trial for InterMune’s Esbriet NDA
May 6, 2010
InterMune has received a complete response letter from the FDA requesting an additional trial for the idiopathic pulmonary fibrosis treatment Esbriet.